deltatrials
Completed PHASE3 NCT00121550

The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease

The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial

Sponsor: Abbott

Conditions Cardiovascular Disease Heart Disease
Interventions clarithromycin
Updated 5 times since 2017 Last updated: Aug 10, 2016 Started: Oct 31, 1999 Primary completion: Apr 30, 2000 Completion: Sep 30, 2002

Listed as NCT00121550, this PHASE3 trial focuses on Cardiovascular Disease and Heart Disease and remains completed. Sponsored by Abbott, it has been updated 5 times since 1999, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abbott
  • Copenhagen Hospital Corporation
  • Copenhagen Trial Unit, Center for Clinical Intervention Research
  • Danish Heart Foundation
  • The 1991 Pharmacy Foundation
  • The Danish Medical Research Council
Data source: Copenhagen Trial Unit, Center for Clinical Intervention Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Copenhagen, Denmark
  • • Frederiksberg, Denmark
  • • Hvidovre, Denmark